List of Mavyret drug patents
Mavyret is owned by Abbvie Inc.
Mavyret contains Glecaprevir; Pibrentasvir.
Mavyret has a total of 20 drug patents out of which 0 drug patents have expired.
Mavyret was authorised for market use on 10 June, 2021.
Mavyret is available in pellets;oral dosage forms.
Mavyret can be used as treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg, treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg, treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg.
Drug patent challenges can be filed against Mavyret from March, 2022.
The generics of Mavyret are possible to be released after 24 December, 2036.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8648037 | ABBVIE INC | Macrocyclic proline derived HCV serine protease inhibitors |
Jan, 2032
(8 years from now) | |
| US8937150 | ABBVIE INC | Anti-viral compounds |
May, 2032
(9 years from now) | |
| USRE48923 | ABBVIE INC | Crystal forms |
May, 2035
(12 years from now) | |
| US9321807 | ABBVIE INC | Crystal forms |
Jun, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10028937 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(7 years from now) | |
| US10039754 | ABBVIE INC | Anti-viral compounds |
Jun, 2030
(7 years from now) | |
| US9586978 | ABBVIE INC | Anti-viral compounds |
Nov, 2030
(7 years from now) | |
|
US10028937
(Pediatric) | ABBVIE INC | Anti-viral compounds |
Dec, 2030
(7 years from now) | |
|
US10039754
(Pediatric) | ABBVIE INC | Anti-viral compounds |
Dec, 2030
(7 years from now) | |
|
US9586978
(Pediatric) | ABBVIE INC | Anti-viral compounds |
May, 2031
(8 years from now) | |
|
US8648037
(Pediatric) | ABBVIE INC | Macrocyclic proline derived HCV serine protease inhibitors |
Jul, 2032
(9 years from now) | |
|
US8937150
(Pediatric) | ABBVIE INC | Anti-viral compounds |
Nov, 2032
(9 years from now) | |
| US10286029 | ABBVIE INC | Method for treating HCV |
Mar, 2034
(11 years from now) | |
| US11484534 | ABBVIE INC | Methods for treating HCV |
Mar, 2034
(11 years from now) | |
|
US10286029
(Pediatric) | ABBVIE INC | Method for treating HCV |
Sep, 2034
(11 years from now) | |
|
US11484534
(Pediatric) | ABBVIE INC | Methods for treating HCV |
Sep, 2034
(11 years from now) | |
|
USRE48923
(Pediatric) | ABBVIE INC | Crystal forms |
Nov, 2035
(12 years from now) | |
|
US9321807
(Pediatric) | ABBVIE INC | Crystal forms |
Dec, 2035
(12 years from now) | |
| US11246866 | ABBVIE INC | Solid pharmaceutical compositions for treating HCV |
Jun, 2036
(13 years from now) | |
|
US11246866
(Pediatric) | ABBVIE INC | Solid pharmaceutical compositions for treating HCV |
Dec, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 3, 2022 |
| M | Apr 10, 2023 |
| New Dosing Schedule (D) | Sep 26, 2022 |
| Orphan Drug Exclusivity (ODE) | Jun 10, 2028 |
| Pediatric Exclusivity (PED) | Mar 26, 2023 |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
NCE-1 date: March, 2022
Market Authorisation Date: 10 June, 2021
Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg
Dosage: PELLETS;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic